A 58-year-old man from rural Maharashtra presents to a primary health centre with acute onset chest pain of 2 hours duration. He describes it as crushing, substernal pain radiating to the left arm, associated with diaphoresis and nausea. His blood pressure is 95/60 mmHg, heart rate 110/min, and respiratory rate 22/min. A 12-lead ECG performed at the PHC shows ST elevation of 3 mm in leads II, III, and aVF with reciprocal ST depression in leads I and aVL. The nearest PCI-capable hospital is 180 km away and would take 4 hours to reach. What is the most appropriate immediate management?

Explanation

## Clinical Scenario Analysis This is an **inferior wall STEMI** (ST elevation in II, III, aVF with reciprocal changes) presenting within the **fibrinolytic window (< 12 hours)** at a **non-PCI-capable facility** with **4-hour transport delay** to the nearest PCI centre. ## Guideline-Based Management **Key Point:** When PCI cannot be delivered within 120 minutes of first medical contact (FMC) at a non-PCI-capable hospital, **fibrinolytic therapy is the reperfusion strategy of choice** [cite:Harrison 21e Ch 297]. **High-Yield:** The 2019 ESC Guidelines and 2015 ACC/AHA Guidelines recommend: - **Fibrinolysis** if PCI-capable hospital > 120 minutes away - **Tenecteplase** is the preferred fibrinolytic agent (single bolus, better outcomes than streptokinase) - **Dual antiplatelet therapy** (aspirin + P2Y12 inhibitor) is mandatory - **Anticoagulation** with heparin or enoxaparin ## Rationale for Tenecteplase | Feature | Tenecteplase | Streptokinase | |---------|--------------|---------------| | Bolus administration | Single IV bolus (weight-based) | 1.5 MU over 60 min | | Fibrin specificity | High | Low | | Reperfusion rate | 84–90% | 60–70% | | 30-day mortality | Lower | Higher | | Ease of use | Superior (PHC-friendly) | Requires infusion pump | **Clinical Pearl:** Tenecteplase 50 mg IV bolus is appropriate for this patient (weight-based dosing: 50 mg for 60–70 kg). It achieves reperfusion in ~60% of cases within 60 minutes. ## Complete Management Bundle 1. **Dual antiplatelet therapy:** - Aspirin 325 mg chewed immediately - Clopidogrel 600 mg (or ticagrelor 180 mg) immediately 2. **Fibrinolytic agent:** - Tenecteplase 50 mg IV bolus 3. **Anticoagulation:** - Unfractionated heparin 60 U/kg bolus (or enoxaparin 0.3 mg/kg) 4. **Arrange transfer** to PCI-capable hospital for: - Rescue PCI if fibrinolysis fails (chest pain persists, no ST resolution at 60–90 min) - Routine PCI 3–24 hours post-fibrinolysis (pharmaco-invasive strategy) **Warning:** Do NOT delay fibrinolysis awaiting transfer. Time is myocardium — every minute of delay increases mortality. ## Why Tenecteplase Over Streptokinase? - **Single bolus:** Easier to administer in resource-limited settings - **Better outcomes:** ASSENT-2 trial showed lower mortality and reinfarction - **Less allergy:** No prior sensitization concerns (unlike streptokinase) - **Faster reperfusion:** Achieves TIMI 3 flow earlier **Mnemonic: TENECTEPLASE advantages = BEST** - **B**olus (single, weight-based) - **E**asy (PHC-friendly) - **S**uperior outcomes - **T**iming (faster reperfusion)